Decision Diagnostics 

$0
7
+$0+0% Friday 20:00

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
2,000,000
Avg. Volume
0
Mkt Cap
35,787.1
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

30NovExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0
-0
-0
0
Expected EPS
0
Actual EPS
0

Financials

-1,499.19%Profit Margin
Unprofitable
2015
2016
2017
2018
2019
2020
3.96MRevenue
-59.34MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DECN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories competes with DECN in the blood glucose monitoring market, offering similar diabetes care products.
Dexcom
DXCM
Mkt Cap22.71B
DexCom, Inc. specializes in continuous glucose monitoring (CGM) systems, directly competing with DECN's glucose testing solutions.
Tandem Diabetes Care
TNDM
Mkt Cap945.97M
Tandem Diabetes Care, Inc. offers insulin pumps and related diabetes management products, competing in the broader diabetes care market.
Medtronic
MDT
Mkt Cap116.33B
Medtronic plc provides a range of diabetes management products, including CGM systems and insulin pumps, competing with DECN's offerings.
Insulet
PODD
Mkt Cap22.03B
Insulet Corporation's Omnipod insulin management system competes in the insulin delivery market, relevant to DECN's diabetes care solutions.
Senseonics
SENS
Mkt Cap287.64M
Senseonics Holdings, Inc. offers implantable CGM systems, competing with DECN's non-invasive glucose monitoring products.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its subsidiary LifeScan, competes in the blood glucose monitoring market, offering products that rival DECN's.
Rogers
ROG
Mkt Cap1.57B
Roche Holding AG offers diabetes care solutions, including glucose monitors and insulin pumps, competing in the same market as DECN.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk A/S, while primarily known for insulin, also competes in the diabetes care market with its range of products.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb Company, through its acquisition of MyoKardia, is involved in cardiovascular care, indirectly competing with DECN's focus on diabetes management as diabetes is a risk factor for cardiovascular diseases.

About

Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips. In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment. Further, the company also provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.
Show more...
CEO
Mr. Keith M. Berman
Employees
6
Country
US
ISIN
US2434431084

Listings

0 Comments

Share your thoughts

FAQ

What is Decision Diagnostics stock price today?
The current price of DECN is $0 USD — it has increased by +0% in the past 24 hours. Watch Decision Diagnostics stock price performance more closely on the chart.
What is Decision Diagnostics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Decision Diagnostics stocks are traded under the ticker DECN.
Is Decision Diagnostics stock price growing?
DECN stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Decision Diagnostics has showed a +0% increase.
What is Decision Diagnostics market cap?
Today Decision Diagnostics has the market capitalization of 35,787.1
What were Decision Diagnostics earnings last quarter?
DECN earnings for the last quarter are 0 USD per share, whereas the estimation was 0 USD resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Decision Diagnostics revenue for the last year?
Decision Diagnostics revenue for the last year amounts to 3.96M USD.
What is Decision Diagnostics net income for the last year?
DECN net income for the last year is -59.34M USD.
How many employees does Decision Diagnostics have?
As of April 01, 2026, the company has 6 employees.
In which sector is Decision Diagnostics located?
Decision Diagnostics operates in the Health Care sector.
When did Decision Diagnostics complete a stock split?
Decision Diagnostics has not had any recent stock splits.
Where is Decision Diagnostics headquartered?
Decision Diagnostics is headquartered in Westlake Village, US.